GSE1919

Rheumatoid arthritis

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

5 case / 5 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Rheumatoid arthritis (RA) is a chronic, inflammatory joint disease of unknown etiology and pronounced inter-patient heterogeneity. To characterize RA at the molecular level and to uncover key pathomechanisms, we performed whole-genome gene expression analyses. Synovial tissues from rheumatoid arthritis patients were compared to those from osteoarthritis patients and to normal donors. Keywords: disease state analysis

Overall design

Two disease conditions (rheumatoid arthritis and osteoarthritis) in comparison to normal donors were investigated. For the two disease groups samples derived from three individual patients and two pools of patients were hybridised.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
15 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Curated expression experiment linkage and source URL.

Expression Atlas accession
E-GEOD-1919
Available
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

21 linked publications 21 DOIs

Primary publication

  1. Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. Physiological genomics, 2010

Related publications

  1. Aquaporin-1 stabilizes β-catenin to promote NLRP3 inflammasome-mediated pyroptosis in rheumatoid arthritis. Apoptosis : an international journal on programmed cell death, 2026
  2. Identification and Experimental Verification of PDK4 as a Potential Biomarker for Diagnosis and Treatment in Rheumatoid Arthritis. Molecular biotechnology, 2025
  3. Lutein attenuates rheumatoid arthritis progression by suppressing MAPK/NF-κB signaling and MMP3 and MMP13 expression in fibroblast-like Synoviocytes. International immunopharmacology, 2025
  4. Identification of key pathways and biomarkers in rheumatoid arthritis synovial tissue through comprehensive transcriptomic integration. Journal of orthopaedics, 2026
  5. Kaempferol alleviates rheumatoid arthritis through pyroptosis based on bioinformatics analysis and experimental validation. Scientific reports, 2024
  6. Identification of Autophagy-Associated Molecular Signatures in Osteoarthritis Revealed by Integrative Multi-Omics and Experimental Validation. Chemical biology & drug design, 2026
  7. Mechanism of immune infiltration in synovial tissue of osteoarthritis: a gene expression-based study. Journal of orthopaedic surgery and research, 2023
  8. Identification of sulfur metabolism-related gene signature in osteoarthritis and TM9SF2's sustenance effect on M2 macrophages' phagocytic activity. Journal of orthopaedic surgery and research, 2024
  9. Programmed cell death-related gene S100A9 promotes macrophage M1 polarization and chondrocyte apoptosis in rheumatoid arthritis. Biology direct, 2026
  10. [Bioinformatics analysis of oxidative stress and immune infiltration in rheumatoid arthritis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2025
  11. Analysis of common differential gene expression in synovial cells of osteoarthritis and rheumatoid arthritis. PloS one, 2024
  12. KIF11 promotes rheumatoid arthritis pathogenesis by activating M1 macrophage polarization and promoting inflammatory cytokine secretion. PloS one, 2026
  13. Decreased serum TIMP4 levels in patients with rheumatoid arthritis. Open life sciences, 2025
  14. Exploration of the Key Pathways and Genes Involved in Osteoarthritis Genesis: Evidence from Multiple Platforms and Real-World Validation. Journal of inflammation research, 2024
  15. Investigating Angiogenesis-Related Biomarkers in Osteoarthritis Patients Through Transcriptomic Profiling. Journal of inflammation research, 2024
  16. Integrated Multi-Level Investigation of Friend Leukemia Integration 1 Transcription Factor as a Novel Immune-Inflammatory Biomarker in Rheumatoid Arthritis: Bridging Bioinformatics, Clinical Cohorts, and Mechanistic Validation. Journal of inflammation research, 2025
  17. Screening and validation for core genes in osteoarthritic cartilage based on weighted gene co-expression network analysis. European review for medical and pharmacological sciences, 2022
  18. Identification of susceptibility modules and hub genes of osteoarthritis by WGCNA analysis. Frontiers in genetics, 2022
  19. Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma. Frontiers in immunology, 2022
  20. Identification of key genes in osteoarthritis development: biomarker discovery and therapeutic targets. Frontiers in medicine, 2025
Available

Metadata Quality Components

Analysis Readiness

Review before analysis
85% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

3/15 pts

Unassigned or review-needed samples remain before analysis.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • 5 samples are still unassigned.

Next Steps

  • Resolve unassigned or review-needed samples in the grouping table.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Needs review

0 review-needed samples and 5 unassigned samples remain.

Resolve ambiguous and unassigned samples before finalizing the contrast.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

One or more samples are unassigned and need manual grouping decisions.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Rheumatoid arthritis Disease context came from Normalization rules.
  • Likely case group Rheumatoid arthritis 5 samples
  • Likely control group Normal tissue 5 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Disease/model vs control. Specimen: Unclear specimen/source. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Interpreted disease metadata: Rheumatoid arthritis.
  • Processed data is available for downstream review.
  • External evidence: Expression Atlas curated experiment link is available.
  • External evidence: PubMed links 21 publications; 21 DOIs available: PMID 20858714, PMID 36389761, PMID 36459007, PMID 36468029, PMID 36681837.
  • Publication context: Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis.. Physiological genomics, 2010. PMID 20858714. DOI 10.1152/physiolgenomics.00004.2010.
  • Publication context: Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma.. Frontiers in immunology, 2022. PMID 36389761. DOI 10.3389/fimmu.2022.1036239.
  • Publication context: Screening and validation for core genes in osteoarthritic cartilage based on weighted gene co-expression network analysis.. European review for medical and pharmacological sciences, 2022. PMID 36459007. DOI 10.26355/eurrev_202211_30355.
  • Publication context: 18 additional linked PubMed publications are available.

Cautions

  • Comparison: Disease/model vs control. Specimen: Unclear specimen/source. Comparison suitability: 0%.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Unclear specimen/source downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear specimen/source downgraded for patient tissue tumor-vs-normal search intent.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Missing or unclear metadata. Comparison - Disease/model vs control. Specimen - Unclear specimen/source. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

14 fields

Sample Group Preview

15 rows shown
Show Hide
Study totals: Case 5 | Control 5 | Unassigned 5 | Excluded 0 | Ambiguous 0 15 rows shown
Group Role Accession Title Source / characteristics Reason
Rheumatoid arthritis Case GSM34398 RA_A Rheumatoid arthritis Age: 45; Gender: Female; Sample 2; Age: 81; Gender: Female Case marker detected.
Rheumatoid arthritis Case GSM34399 RA_B Rheumatoid arthritis Age: 51; Gender: Male; Sample 2; Age: 84; Gender: Female; Age: 74; Gender: Female Case marker detected.
Rheumatoid arthritis Case GSM34400 RA_x Rheumatoid arthritis Age: 44; Gender: Female Case marker detected.
Rheumatoid arthritis Case GSM34401 RA_y Rheumatoid arthritis Age: 49; Gender: Female Case marker detected.
Rheumatoid arthritis Case GSM34402 RA_z Rheumatoid arthritis Age: 63; Gender: Male Case marker detected.
Normal tissue Control GSM34379 ND_1 Normal donor Age: 69; Gender: Female; Age: 64; Gender: Male; Age: 75; Gender: Male; Age: 58; Gender: Male Control marker detected.
Normal tissue Control GSM34383 ND_2 Normal donor Age: 58; Gender: Male; Sample 2; Age: 58; Gender: Male; Age: 57; Gender: Male; Sample 4; Age: Unknown; Gender: Unknown Control marker detected.
Normal tissue Control GSM34385 ND_3 Normal donor Age: 32; Gender: Female; Sample 2; Age: 47; Gender: Male; Sample 3; Age: 75; Gender: Female Control marker detected.
Normal tissue Control GSM34388 ND_4 Normal donor Age: 46; Gender: Male; Sample 2; Age: Unknown; Gender: Unknown Control marker detected.
Normal tissue Control GSM34391 ND_5 Normal donor Age: 58; Gender: Male; Sample 2; Age: Unknown; Gender: Unknown Control marker detected.
Unassigned Unassigned GSM34393 OA_A Osteoarthritis Age: 60; Gender: Female; Sample 2; Age: 77; Gender: Male No explicit case or control marker detected.
Unassigned Unassigned GSM34394 OA_B Osteoarthritis Age: 58; Gender: Female; Sample 2; Age: 77; Gender: Male No explicit case or control marker detected.
Unassigned Unassigned GSM34395 OA_x Osteoarthritis Age: 86; Gender: Female No explicit case or control marker detected.
Unassigned Unassigned GSM34396 OA_y Osteoarthritis Age: 69; Gender: Female No explicit case or control marker detected.
Unassigned Unassigned GSM34397 OA_z Osteoarthritis Age: 68; Gender: Female No explicit case or control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.